Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study
Against the background of the ongoing coronavirus disease 2019 (COVID-19) pandemic, huge disruptions have occurred in healthcare access, social interactions and economic activity. Vaccines have been developed at a highly accelerated pace to end the suffering earlier and at a lower cost than would be achievable by allowing the virus to take its course.
However, the dosage, the immunization schedule, the duration and the breadth of resulting immunity are still matters of study even as over a dozen vaccines are already under emergency use nationwide in many different countries the world over. The logistical difficulties, delay in vaccine supplies, and shortage of manufactured doses have combined to slow the rate of vaccination to the point that it appears unlikely that adequate global coverage will be accomplished within the next two years.